for cash-strapped NWBO it would make perfect sense.

There is vivid trading in claimed damages in the legislation industry, you should know that.

ex even you have to admit that when to me and if for you DCVAXL is approved (FDA, even MHRA) large big pharma's will want to buy NWBO.

flipper could the $3 million not be NWBO selling a portion of the court ruling outcome (if positive of course) or a settlement (against a multiplier) to keep the lights on?

I think this would make perfect sense.

For Advent to be able to have more clients than NWBO Advent should have at least a sales and or marketing department and there is still no sign of any Advent employee/staff fulfilling those tasks.
https://www.linkedin.com/company/advent-bioservices/people/

Still, as I have always said given the fact that NWBO for a large part paid for Advent being able to start and exist, NWBO should at least own 75% of Advent Bio Ltd. Alas LP/Toucan wants it all. The upside of this huge conflict of interest is that LP is now more motivated to sell NWBO for an incredibly nice price satisfying all NWBO shareholders to avoid lawsuits. But that's my always look at the bright side of life, take on it.

Tremendous nonsense absolute BS
One has very little todo with the other

PM only after MHRA approval they will enter in a deal with a big pharma. Won’t be long until we see MAA accepted

Ps I’m not lying

BS the FDA does allow SAP / endpoints to be amended even AFTER datalock. It’s laughable amusing and disturbing how you dont even pretend to do some sort of survey before you post you utter rubbish

You wanne bet I say its going to happen

1. You absolutely in no way shape or form can compare the time when NWBO was building the production facility for DCVAXL and maintaining a trial to the cost of the present day.

Second Im 75% convinced that NWBO will disappear (as in will be bought) between now and 9 months max 1 year

Third if not bought then after approval the SP will be much higher thus less dilution

4th I dont see NWBO management exercising any options or warrants ever but being bought off on the day NWBO is acquired. So technically we will never see those warrants and options translated into O/S

5Th you dont know what the number of C prefs are.

6th was it 477 million shares for management and staff? I thought it was 250 million?

No, you dont.
The pitfall of all pre-park bench sleepers is overestimating him/her self.

If you are such an expert on what NWBOs future will be like, why didn't you sell when the stock was at +$2 a year and 3 weeks ago when you knew the future of NWBO would be a 55-cent stock 1 year and 3 weeks later?

You dont know that, you are guessing this.

There will be no 5 years future for NWBO they will have been bought long before that.
The authorized shares of 1.7B will be including management's share of the pie, for management to convert their options and warrant into shares.

But you don't know if long before 1.7B is reached they are acquired. Chances are they ar.

You know why your claim is unsustainable and also why there is another reason we will see NWBO and Advent bought shortly. Advent staff.

Now when it comes to NWBO there may be a certain apathy and doing nothing for half a dozen of its employees is just fine, but not for Advent. Contrair of NWBO Advent has a vibrant ambitious young staff who you want to keep employed in today's difficult labor market. If Advent employees are not fed with challenging assignments such as the development of cell therapy aka DCVAXL but instate are just being paid for sitting around doing nothing then they will leave. Without Advent's highly skilled employees, there is no Advent for Toucan.

It must be therefore LP's high priority to as soon as possible provide the 54+ Advent employees with challenging work they have been hired for (among others a patient liaison) otherwise they will leave. Also, you just can't keep asking NWBO to fund the salaries of 54 people for being available for many months even years, as you claim, for the promise of maybe future production of DCVAXL.

Now I know what you will say Advent has other clients. Yes, some small. But not to keep the 54+ highly educated staff challenged and Advent 100% financed. As soon as NWBO and Advent are bought by Merck they will provide great production assignments for Advent staff.
Its of the highest priority for LP to speed up BLA and MAA for all these reasons.

If I had to guess then it's yesterday's NYC audience that is buying in. Hopefully we will see MAA one of these days

Anyone saying BO after birds land south of Dakota mountains. Doubt birds would fly anywhere near the black mountains with a deal in hand or in close negotiations

Yes I believe EDEN is a maybe far in the future project and for the coming years its manual.

Im sticking with the official head count on LinkedIn. I dont believe in secret NWBO employees no one has ever heard of.

EDEN is not a prerequisite for approval its not what NWBO has requested approval for any time soon and its not a prerequisite for a buyout. In the coming years its manual manufacturing. EDEN has taken a back seat in NWBO's business development which is why EDEN's lead developer left last summer.

Its really not that complicated what you see is what you get.

No they haven't. Do you have a link to prove that?
Flaskworks employs 5 people of which 3 actually work on EDEN
https://www.linkedin.com/company/flaskworks/people/

Why would anyone working at Advent secretly work for Flaskworks?
Of the 54 people working for Advent non from their LinkedIn job description can be contributed to EDEN https://www.linkedin.com/company/advent-bioservices/people/

So I assume you just are guessing a dozen are working on EDEN?

That would be the worse case scenario yes and one where we will have to wait many many months before they request for approval.

it's nearly impossible to lie about what happened in future events.
Dennis

You can keep that quote ;)

thanks.
well. Its not only adding a few positions. Its adding hundreds of them in an already very tight labor market. Novocure has 1,167 employees, and Kite Pharma had 700 before they were bought. Just bought Prometheus Biosciences total number of employees in 2022 was 97.
If you would add the number of staff working at Advent(54) to NWBO (15) we are looking at 69 in total (I personally believe Merck will buy Advent together with NWBO).

Look at how long it took Advent to add 54 people to its staff. If NWBO would want to stay independent it would take many years after approval to get to a team of at least 600-700 needed to become some form of mid-independent large biotech. They really should have started building a team, on thin finances, 2 years ago.

I have not seen any on LinkedIn or anywhere else.
Exactly. Advent did hire one staff as a patient liaison. I think that for the rising demand for compassionate use.

If there was an announcement being put up in front of every investor's home by the Gods of the stock market and God of M&A which listed companies will be bought in the next 12 months then investing was easy and everyone would get rich.

The only question we have to concern ourselves with going forward is, will DCVAXL be approved if yes then they will be also bought out. Anyone claiming NWBO will become an independent cancer biotech giant really has to recheck reality.

That's why we are not already bought by now and Merck (if it's Merck) will want to wait until after approval and not as in the case with Prometheus prior to that.

30 days after MHRA, NWBO would be acquired? That would be fantastic.

This is what I think what is going to happen for the next 1.5 years:
MHRA request for approval: SP to 90 cents. May or June
FDA request for approval 1 or 2 months later: SP to around $2 July or August
MHRA approval Oct: Sp to around $4 in the weeks after
Uplist announcement SP to 5$ in Dec 2023 MC around $ 6B
FDA approval May - June 2024, speculation on BO media SP to around $ 10 MC 15B
BO Sept -Oct 2024 for $24B, at a SP of around $16

It would not surprise me either. Im convinced Eden does not play any role in the acquisition of NWBO. If it was a prerequisite for NWBO acquisition then Staff working on Eden would be many more than 2 as it is now. Also, it would be incredibly unrealistic for Merck to demand Eden to be certified before acquiring NWBO since Eden is just not where the state of technology is right now. NWBO has put Eden on the backseat for now with 2 working on the project and the main engineer vanished and not being replaced. Then Im coming back to what I posted before. Where is the DCVAXL sales team? Even if NICE has not appraised DCVAXL after approval yet, still NWBO should in that case start preparing sales and could already start selling and marketing it.

No, Im convinced NWBO will be acquired after either MHRA or FDA approval. That is not years but within 6-12 months max after MHRA approval.

Agreed that is a key turning point for the company

Im not sure either if the BO will be after FDA or MHRA approval. After everything is submitted to the FDA and the MHRA, and the MHRA has granted approval Merck (if its Merck) will know FDA approval is just a formality.

I do believe 10 billion is too low of a buyout price given the fact that Merck is paying $10.8 billion for a company with no approved drugs (Prometheus Biosciences), so it is reasonable to pay at least x2 that amount for NWBO.

The combo trial is paid and done, its in the history books. We are only waiting to learn how fantastic the end results are. You don't need a CFO for that.

The point I'm making is that if you're a young and vibrant biotech, with a vision for the next stage of your company and (near future) approved biotech product and a vision for your next big medical trial you desperately need a CFO to prepare for the tens if not hundreds of millions to finance your next big medical trial and the selling and marketing of your approved product. There is zero indication NWBO is remotely interested in dong so.

The absence of a CMO means to they are not preparing to initiate another clinical trial.
The absence of a CFO means they are not preparing for long-term management of the financial actions of the company, especially when there is not going to be another medical trial.
They are not putting together a sales team to sell DCVAXL, not renewing their website, and not adding/replacing younger management to NWBO staff.

Conclusion: NWBO will be bought as I have said not far after approval.

Mercks SP is up 25% because numbers were better than expected year over year.
There is no Merck shareholder selling or anyone shorting Merck because of some patent, Merck probably has hundreds of patents.

Merck's shareholders are not occupying themselves with any patent cliff, but Merck management is.

Look this isnt rocket science. 90% of small biotech fail and will never get any approval.
The 10% of the remaining biotech will 90% of the time get bought out.
Big Pharma lives and breathes by buying successful or semi-successful small biotech.
I am sure Merck's shareholders expect Merck to keep buying successful small biotechs with their tremendous cash position to safeguard their successful cash-generating drug pipeline.
After DCVAXL is approved NWBO will be bought Im 99% sure of that.

and how many of these many elements of Mercks overall long-term picture will gain approval?
After DCVAXL has been approved Dcavxl will be standing out taller than the Statue of Liberty from all the other players Merck is considering replacing Keytruda with. Approval is key after that there will be a bidding war for NWBO.

that's a guy who gets it, until of course his wife as would mine summons him back to the table she is sitting at and they started the evening. Im starting to see a marriage patron here

heheheheheh married for 8 years now and if my wife says marriages are based on trust then it is the law lol

Marriages are suppose to be based on trust PM, Are you sure your wife is mad about you because of NWBO?

I have very little doubt NWBO will be acquired, Im not sure if its after MHRA or after FDA approval.

Just to be clear its not Seeking Alpha opinion its a "frivolous lawsuit appears to be nothing more than an attempt by Northwest Biotherapeutics to divert attention". He was quoting Canaccord Genuity and Citadel Securities



But yes by mid-July we will have more feedback on the lawsuit but more important hopefully also on the submitting of the MAA/BLA. Exciting months ahead :)

no its of course incredible reasonoble. However, after all these years of holding NWBO stock Im used to their unusual behavior and it can be concluded that they will not change in this regard. Im also tired of complaining so I have stopped doing so.

Next 18 months:
MAA / BLA submission, FDA/UK approval, Uplist Buy Out, Bye :)

Its not as if we are at the beginning of the phase 3 trial and we had to go through many agonizing years of no news and waiting.

ooh ok.
well
The last two times he published about NWBO he was angered that there still was no TLD/JA 2 weeks later there was and then last Feb he was angered there was no MIA 1 month later there was so now he is angered that there is still no BLA/MAA. :)

Im sorry who is saying this

Im sure NWBO will file BLA/MAA soon

sure

https://seekingalpha.com/article/4598243-northwest-bio-great-data-but-nothing-else?mailingid=31327479&messageid=2800&serial=31327479.4753&utm_campaign=rta-stock-article&utm_medium=email&utm_source=seeking_alpha&utm_term=31327479.4753

N orthwest Bio: Data Is Great, But Nothing Else Is

Apr. 30, 2023 4:06 AM ETNorthwest Biotherapeutics, Inc. (NWBO)
Avisol Capital Partners profile picture
Avisol Capital Partners
Investing Group Leader
Summary

NWBO continues to slog away, with no definite date of a BLA submission.
They recently made provisions for a large dilution, took a "toxic" loan, and got a manufacturing approval in the UK.
There's progress, but it is agonizingly slow, and the stock keeps falling.
Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »
Risk management and mitigation to reduce exposure for financial investment, projects, engineering, businesses. Concept with manager"s hand turning knob to low level. Reduction strategy.
NicoElNino

I would like to begin this article about Northwest Biotherapeutics (OTCQB:NWBO) by quoting the very first paragraph of my February coverage:

I cover NWBO because I appreciate the engagement with (NWBO followers). Enthusiasm, however, cuts both ways. Enthusiasm can make you very knowledgeable about something, but it can also produce tunnel vision. If there was no such tunnel vision, we would realize that Northwest Bio, being a public company, has a duty to keep its investors informed about the company in a timely, clear and dialogic manner, like other companies do with earnings calls. Northwest Bio has never had an earnings call in living memory.

The stock is down 30% since that time, and exactly because of this - no further information from the company since they published those outstanding results last year.

To be precise, that is not exactly true - it did publish stuff, just not what investors wanted to know. On January 6, the company published details about the Annual Shareholders Meeting held on December 30, 2022. A few key points relevant to our discussion are:

Authorization to issue 500 million additional common shares, which increases the number of authorized common shares by 50%.

Review of progress in 2022, which includes data, JAMA publication, and lawsuit - I have discussed each of these in my previous coverages.

Obtained regulatory approval of a Pediatric Investigation Plan (PIP) to support the use of DVax-L in children.

Progress on preparing the Trial Master File to be inspection-ready for regulators.

Preparation for application for commercial manufacturing license for the Sawston facility, a prerequisite for approval.

About the BLA, all that they said was that they are working on an application package, and plans to submit an application "as soon as possible" - this is probably what is eating away at the value of the stock, because normal companies do not take years to submit a BLA, and they generally indicate a timeline.

With reference to item 5, the company received a commercial manufacturing license in the UK in March, for its Sawston facility. The license to manufacture a cell therapy is rare, with only two others given so far. The license allows them to import products such as immune cells, and manufacture and globally export cell therapy products manufactured at their GMP facility in Sawston. In their latest 10-K, they give some details about capacity. They claim that they have the "potential capacity to produce dendritic cell vaccines for up to 40 to 45 patients per month, or approximately 450 to 500 patients annually."

With respect to item 1, I have noted again and again that this $528mn company with supposedly/apparently excellent data has no cash. Since they issued 500 million additional common shares, that is a big concern because that means potential dilution to a very large extent. In March, they signed a $11mn loan deal with John M. Fife's Streeterville Capital. The deal has a maturity of 22 months, and debt repayments will begin from November 02, when the loan will be amortized in 14 equal monthly installments of principal plus interest. That means, from November, NWBO will have to start paying approximately $1mn per month for 14 months to the lender. Two years back, NWBO took a similar loan from the same lender.

A year before that, the SEC charged John Fife "for acquiring and selling more than 21 billion shares of penny stock without registering as a securities dealer with the SEC." Here's what has been said about the mode of operation of these so-called "toxic lenders":

Fife has operated as what's called a "toxic lender" for many years. Microcap companies trading on the over-the-counter market typically have limited access to traditional financing. Desperate for cash, they sign on with financiers like Fife who purchase securities-usually convertible promissory notes or convertible debentures-from them. The financiers charge extremely high interest, but that's the least of their clients' problems. Upon conversion, the lenders enjoy a discount to market price that may be as high as 60 percent, and higher in the event of default by the issuer. As he converts portions of his note and sells the resulting stock into the market in a series of tranches, the stock's price plummets. That is why these kinds of instruments are called "death spiral convertibles." Eventually, the dilution caused by the conversions may force the issuer to reverse split the company's stock. Sometimes it drives the company into bankruptcy.

So, Northwest Bio has a) very little cash, and b) very little access to good loans, so c) they take a loan from this controversial lender, from whom d) they took a loan earlier, whose fate is uncertain, and e) they just allowed themselves to dilute shareholder value in future, by half, so f) the conclusion is that the cash position and dilution situation remains precarious for a company which claims to have arrived at very strong results in a cancer indication.

The only item left to discuss is the "spoofing" lawsuit filed by the company against 8 of the largest market makers in the US, including Canaccord Genuity and Citadel Securities. In a statement, the latter said:

This frivolous lawsuit appears to be nothing more than an attempt by Northwest Biotherapeutics to divert attention away from its long history of governance and management failures, SEC charges for financial reporting lapses, and lawsuits from its own shareholders.

In March, I see a note on law360 (which I cannot fully access), which says these companies have asked a federal judge to toss the suit, saying "the case fails to allege any actionable trading or evidence of misconduct." So, the lawsuit is ongoing, and it is, whatever its merit, a major distraction from the company's main business of developing and selling a cancer therapy product.

So that is it. These are what happened to NWBO recently. They also explain, once again, why the stock has been cut by half in the last few months since the data. They have no cash, and they are offering no timeline for a BLA submission. I have a few shares, I am not making a profit right now, and I will continue to hold.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.